Taysha Gene Therapies, Inc. TSHA 深 滬
等待開盤 09-25 09:30:00 美东时间
4.745
-0.165
-3.36%
華盛通- 最 高4.88
- 今 開4.88
- 成交量 325.14万股
- 最 低 4.655
- 昨 收 4.91
- 總市值 15.46亿
- 52周最高 7.30
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 3.6929
- 委 比 -23.13%
- 總股本 3.26亿
- 歷史最高 33.35
- 量 比 1.26
- 振 幅 4.58%
- 歷史最低 0.50
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
09-17 22:08
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted 5 new employees 314,000 RSUs and options to purchase 92,400 shares under its 2023 Inducement Plan. The RSUs vest over 4 years, and the stock options have an exercise price of $5.70, vesting similarly with a 10-year term. The company focuses on AAV-based gene therapies for CNS diseases.
09-04 12:00
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.
08-12 20:01
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.
08-12 04:00
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have entered into a commercial supply agreement for TSHA-102, a gene therapy for Rett syndrome. Catalent will serve as Taysha's primary manufacturer following potential FDA approval, leveraging its expertise in gene therapy manufacturing. This partnership aims to secure long-term commercial production capacity and scalable supply to meet future demand. Rett syndrome is a rare neurodevelopmental disorder caused b...
08-03 12:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13
Goldman Sachs analyst Salveen Richter maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $11 to $13.
07-21 20:43
Taysha Gene Therapies shares are trading lower after a Form 4 filing showed its President and Head of R&D sold 200,000 shares at an average price of $6.24 each.
Taysha Gene Therapies shares are trading lower after a Form 4 filing showed its President and Head of R&D sold 200,000 shares at an average price of $6.24 each.
07-13 22:24
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and maintains $11 price target.
07-02 20:56
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
